Novo Nordisk CEO on Medicare coverage, new obesity pill, U.S. pricing pressure

Novo Nordisk CEO Mike Doustdar tells CNBC that Medicare coverage for obesity treatments, as well as the launch of a new obesity pill, should help boost prescription volumes and offset lower prices.